Acute Myeloid Leukemia in Children: Standard of Care and Future Perspectives

Tomizawa, Daisuke, Kolb, Edward Anders, Reinhardt, Dirk

Acute Myeloid Leukemia in Children: Standard of Care and Future Perspectives
  • 出版商: Springer
  • 出版日期: 2024-08-21
  • 售價: $5,710
  • 貴賓價: 9.5 折 $5,425
  • 語言: 英文
  • 頁數: 458
  • 裝訂: Hardcover - also called cloth, retail trade, or trade
  • ISBN: 3031633652
  • ISBN-13: 9783031633652

    • 海外代購書籍(需單獨結帳)

相關主題

商品描述

This book provides up-to-date information on key topics and issues in Pediatric Acute Myeloid Leukemia (AML), including the epidemiology, biology, diagnosis and treatment of particular forms of the disease, supportive care, and survivorship. The entire spectrum of clinical management on pediatric AML is covered with the aim of equipping readers with the latest knowledge relevant to clinical practice and research, based on enormous efforts made by cooperative clinical trial groups and consortia worldwide. Each chapter is written by internationally renowned authorities who have been selected for their expertise in the subjects discussed. This book will serve pediatric hematologists/oncologists, fellows, and residents both as a comprehensive source of information and as a quick reference. The book will also be of interest to pediatricians and general practitioners.

商品描述(中文翻譯)

本書提供了關於小兒急性骨髓性白血病（AML）的關鍵主題和問題的最新資訊，包括流行病學、生物學、診斷和治療特定形式的疾病、支持性護理和生存率。本書涵蓋了小兒AML臨床管理的整個範譜，旨在為讀者提供與臨床實踐和研究相關的最新知識，這是全球合作臨床試驗團體和聯盟所做出的巨大努力的結果。每一章節都由國際知名專家撰寫，他們在所討論的主題上具有專業知識。本書將作為小兒血液學/腫瘤學專家、住院醫師和住院醫師的綜合資訊來源和快速參考。本書也對小兒科醫師和全科醫師具有興趣。

作者簡介

Dr. Daisuke Tomizawa is a pediatric hematologist/oncologist and Head of the Division of Leukemia and Lymphoma at the Children's Cancer Center, National Center for Child Health and Development in Tokyo, Japan. He served as Vice Chair of the Japan Children's Cancer Group (JCCG) acute myeloid leukemia (AML) disease committee from 2010-2019 and Chair from 2019-2023, which is responsible for the design and conduct of clinical trials and linked translational research studies that enroll approximately 80% of Japanese children and adolescents with this disease. He is also involved in various international research projects in collaboration with North American, Western European, and Asian investigators in this field.

Dr. Edward Anders Kolb is a pediatric hematologist/oncologist, and most recently served as Chief of the Division of Hematology and Oncology of Nemours Children's Health, Wilmington, Delaware, and Professor of Pediatrics, Sidney Kimmel Medical College at Thomas Jefferson University. Dr. Kolb also served as Chair of the Children's Oncology Group (COG) Myeloid Disease Committee from 2013-2023, which is the largest pediatric AML research consortium in the world. He is a strong advocate for international collaboration and leads the development of several international clinical trials. Since 2023, Dr. Kolb was appointed as President and Chief Executive Officer, The Leukemia & Lymphoma Society (LLS) in its mission to cure blood cancers and improve the quality of life for patients and their families.

Prof. Dr. Dirk Reinhardt is a pediatric hematologist/oncologist and Head of Pediatrics III, Pediatric Hematology, Oncology and Stem Cell Therapy at the University Children's Hospital Essen, Germany. He is chairman of the AML-BFM study group, which conducts clinical trials as well as basic and translational research on pediatric AML. As Managing Director of the German Society for Pediatric Oncology and Hematology (GPOH gGmbH) and Director of the EuPAL Foundation, he promotes international projects in drug and therapy development for the treatment of cancer and leukemia in children.

作者簡介(中文翻譯)

Dr. Daisuke Tomizawa是一位小兒血液學家/腫瘤學家，並擔任日本東京國立小兒健康與發展中心兒童癌症中心白血病和淋巴瘤部門的負責人。他在2010年至2019年期間擔任日本兒童癌症團體(JCCG)急性骨髓性白血病(AML)疾病委員會的副主席，並在2019年至2023年期間擔任主席。該委員會負責設計和執行臨床試驗以及相關的轉譯研究，約有80%的日本兒童和青少年參與該疾病的試驗。他還與北美、西歐和亞洲的研究人員合作參與各種國際研究項目。

Dr. Edward Anders Kolb是一位小兒血液學家/腫瘤學家，最近擔任德拉瓦州威明頓Nemours兒童健康的血液學和腫瘤學部門主任，以及賽德尼·金墨爾醫學院兒科教授。Kolb博士還在2013年至2023年期間擔任兒童腫瘤學團體(COG)骨髓性疾病委員會的主席，該委員會是全球最大的小兒AML研究聯盟。他是國際合作的堅定支持者，並領導了多個國際臨床試驗的開發。自2023年以來，Kolb博士被任命為白血病和淋巴瘤協會(LLS)的總裁兼首席執行官，該協會致力於治愈血液癌症並改善患者及其家人的生活質量。

Dirk Reinhardt教授是一位小兒血液學家/腫瘤學家，並擔任德國埃森大學兒童醫院兒科三部門的主任，負責小兒血液學、腫瘤學和幹細胞治療。他是AML-BFM研究小組的主席，該小組在小兒AML方面進行臨床試驗以及基礎和轉譯研究。作為德國兒童腫瘤學和血液學學會(GPOH gGmbH)的經理和EuPAL基金會的主任，他促進了國際項目，致力於發展用於治療兒童癌症和白血病的藥物和療法。

類似商品